Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This trial is conducted in Europe. The aim of this trial is to compare the efficacy of metformin and repaglinide used alone or combined administered as initial treatment in subjects with type 2 diabetes in which diet and exercise have failed.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Met | Experimental |
| |
| Rep | Active Comparator |
| |
| Met+Rep | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| metformin | Drug | Adminstered orally during the three main meals for 24 weeks |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Change of % HbA1c (glycosylated haemoglobin) in blood |
| Measure | Description | Time Frame |
|---|---|---|
| Change of the mean body mass index calculated as weight in kilograms divided by the square of height in metres | ||
| Incidence of clinical and/or biochemistry hypoglycaemia episodes | ||
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Global Clinical Registry (GCR, 1452) | Novo Nordisk A/S | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novo Nordisk Investigational Site | Barcelona | 08020 | Spain | |||
| Novo Nordisk Investigational Site |
Not provided
| Label | URL |
|---|---|
| Clinical Trials at Novo Nordisk | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| repaglinide |
| Drug |
Administered orally before the three main meals for 24 weeks |
|
| Incidence of adverse events |
| Presence of laboratory abnormalities in routine blood analyses |
| Change of the blood pressure and/or heart rate |
| Treatment compliance |
| Benamargosa |
| 29718 |
| Spain |
| Novo Nordisk Investigational Site | Burlata | 31600 | Spain |
| Novo Nordisk Investigational Site | Camas | 41900 | Spain |
| Novo Nordisk Investigational Site | Fuenlabrada | 28942 | Spain |
| Novo Nordisk Investigational Site | Gijón | 33212 | Spain |
| Novo Nordisk Investigational Site | Granada | 18012 | Spain |
| Novo Nordisk Investigational Site | Lugo | 27004 | Spain |
| Novo Nordisk Investigational Site | Madrid | 28021 | Spain |
| Novo Nordisk Investigational Site | Madrid | 28030 | Spain |
| Novo Nordisk Investigational Site | Madrid | 28035 | Spain |
| Novo Nordisk Investigational Site | Portugalete | 48920 | Spain |
| Novo Nordisk Investigational Site | San Adria Del Besos | 08930 | Spain |
| Novo Nordisk Investigational Site | Santander | 39009 | Spain |
| Novo Nordisk Investigational Site | Santander | 39011 | Spain |
| Novo Nordisk Investigational Site | Tegueste | 38280 | Spain |
| Novo Nordisk Investigational Site | Valencia | 46021 | Spain |
| Novo Nordisk Investigational Site | Zaragoza | 50007 | Spain |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D008687 | Metformin |
| C072379 | repaglinide |
| ID | Term |
|---|---|
| D001645 | Biguanides |
| D006146 | Guanidines |
| D000578 | Amidines |
| D009930 | Organic Chemicals |
Not provided
Not provided